Entyvio 300 mg Lyophilized powder for concentrate for solution for infusion., White to off-white lyophilised cake or powder.
PDF Leaflet Revision Date: 8 July 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Indicated for moderate to severe ulcerative colitis and Crohn's disease.
Dosage (summary)
300 mg IV at weeks 0, 2, 6, then every 8 weeks; may increase to every 4 weeks if needed.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not established; use contraception during treatment; present in breast milk.
Key Drug Interactions
- Corticosteroids
- Immunomodulators
- Live vaccines
Contraindications
- Hypersensitivity
- Active severe infections
- Pregnancy
Common side effects
- Headache
- Nasopharyngitis
- Arthralgia
- Infusion-related reactions
Counselling Points
- Administer in a healthcare setting
- Monitor for infections
- Avoid live vaccines
Serious warnings
- Monitor for hypersensitivity reactions
- Risk of infections
- Potential for PML
Important Disclaimer
The Entyvio 300 mg Lyophilized powder for concentrate for solution for infusion., White to off-white lyophilised cake or powder. professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
